Insulin induced lipodystrophy
DOI:
https://doi.org/10.15277/bjdvd.2014.036Abstract
Insulin induced lipoatrophy and, more commonly, lipohypertrophy are dermatological complications of insulin therapy. Lipoatrophy is becoming less common with the advent of newer insulin analogues; however, lipohypertrophy is still prevalent. Whilst an immunological mechanism is postulated for lipoatrophy, direct local anabolic action of insulin is postulated for lipohypertrophy. Other factors which are implicated are the duration of diabetes, the number of insulin injections, re-use of needles and pen devices. The best current preventative and therapeutic strategies for insulin induced lipohypertrophy include rotation of injection sites with each injection and non-reuse of needles. Topical dexamethasone injections have been tried for the management of insulin induced lipoatrophy. It is important that these complications are recognised and managed appropriately. Insulin absorption from these sites is unpredictable and can lead to erratic glycaemic levels and unpredictable hypoglycaemic attacks. This article raises awareness of the possibility of insulin induced lipodystrophy as a cause of poor glycaemic control.References
Garg A. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. JCEM 2011;96:3313-25.
Richardson T, Kerr D. Skin-related complications of insulin therapy. Am J Clin Dermatol 2003;4(10):661-7. http://dx.doi.org/10.2165/00128071-200304100-00001
Hussein SF, Siddique H, Coates P, et al. Lipoatrophy is a thing of the past, or is it? Diabet Med 2007;24:1470-2. http://dx.doi.org/10.1111/j.1464-5491.2007.02300.x
Ma X, Lv H, Li Q, et al. Severe lipoatrophy with insulin in type 1 diabetes. J Dermatol 2012;39(6):578-9. http://dx.doi.org/10.1111/j.1346-8138.2011. 01415.x
Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993;16 Suppl 3:155-65.
Sackey AH. Images in clinical medicine. Injection-site lipoatrophy. NEJM 2009;361:e41. http://dx.doi.org/10.1056/NEJMicm0808275
Wallymahmed ME, Littler P, Clegg C, et al. Nodules of fibrocollagenous scar tissue induced by subcutaneous insulin injections: a cause of poor diabetic control. Postgrad Med J 2004;80:732-3. http://dx.doi.org/10.1136/pgmj.2004.019547
Hambridge K. The management of lipohypertrophy in diabetes care. Br J Nurs 2007;16:520-4. http://dx.doi.org/10.12968/bjon.2007.16.9.23428
Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes 1996;104(2):106-10. http://dx.doi.org/10.1055/s-0029-1211431
Reeves WG, Allen BR, Tattersall RB. Insulin-induced lipoatrophy: evidence for an immune pathogenesis. BMJ 1980;280:1500-03. http://dx.doi.org/10.1136/bmj.280.6230.1500
Raile K, Noelle V, Landgraf R, et al. Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes 2001;109:393-6. http://dx.doi.org/10.1055/s-2001-18991
Radermecker RP, Pierard GE, Scheen AJ. Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. Am J Clin Dermatol 2007;8:21-8. http://dx.doi.org/10.2165/00128071-200708010-00003
Atlan-Gepner C, Bongrand P, Farnarier C, et al. Insulin-induced lipo- atrophy in type I diabetes. A possible tumor necrosis factor-alpha- mediated dedifferentiation of adipocytes. Diabetes Care 1996;19:1283-5. http://dx.doi.org/10.2337/diacare.19.11.1283
Holstein A, Stege H, Kovacs P. Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. Expert Opin Drug Safety 2010;9:225-31. http://dx.doi.org/10.1517/14740330903496402
Chantelau EA, Praetor R, Praetor J, et al. Relapsing insulin-induced lipo-atrophy, cured by prolonged low-dose oral prednisone: a case report. Diabetol Metab Syndr 2011;3:33. http://dx.doi.org/10.1186/1758-5996-3-33
Lopez X, Castells M, Ricker A, et al. Human insulin analog--induced lipoatrophy. Diabetes Care 2008;31:442-4. http://dx.doi.org/10.2337/dc07-1739
Fujikura J, Fujimoto M, Yasue S, et al. Insulin-induced lipohypertrophy: report of a case with histopathology. Endocr J 2005;52:623-8. http://dx.doi.org/10.1507/endocrj.52.623
Wright AD, Walsh CH, Fitzgerald MG, et al. Very pure porcine insulin in clinical practice. BMJ 1979;1:25-7. http://dx.doi.org/10.1136/bmj.1. 6155.25
Frid A, Hirsch L, Gaspar R, et al. New injection recommendations for patients with diabetes. Diabetes Metab 2010;36 Suppl 2:S3-18. http://dx.doi.org/10.1016/S1262-3636(10)70002-1
Roper NA, Bilous RW. Resolution of lipohypertrophy following change of short-acting insulin to insulin lispro (Humalog). Diabet Med 1998;15:1063-4. http://dx.doi.org/10.1002/(SICI)1096-9136(1998120)15:12<1063::AID-DIA706>3.0.CO;2-V
Kumar O, Miller L, Mehtalia S. Use of dexamethasone in treatment of insulin lipoatrophy. Diabetes 1977;26:296-9. http://dx.doi.org/10.2337/diab.26.4.296
Whitley TH, Lawrence PA, Smith CL. Amelioration of insulin lipoatrophy by dexamethasone injection. JAMA 1976;235:839-40. http://dx.doi.org/10.1001/jama.1976.03260340045021
Ramos AJ, Farias MA. Human insulin-induced lipoatrophy: a successful treatment with glucocorticoid. Diabetes Care 2006;29:926-7. http://dx.doi.org/10.2337/diacare.29.04.06.dc06-0004
Published
Issue
Section
License
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.
